Patent ID: 6525033
Filing Date: 2003-02-25
Classification: A61K,A61P

Abstract:
A method for the treatment of HBV infection in a human or other host animal, comprising administering an HBV treatment amount of a nucleoside of the structure: wherein: R1 is hydrogen, fluoro, bromo, chloro, iodo or methyl;R2 is OH, Cl, NH2, or H; R3 is hydrogen; C1-C20 alkyl; acyl in which the non-carbonyl moiety of the ester group is selected from straight, branched; or cyclic C1-C20 alkyl, phenyl, or benzyl; a naturally occurring or nonnaturally occurring amino acid; alkoxyalkyl including methoxymethyl; aralkyl including benzyl; aryloxyalkyl such as phenoxymethyl; aryl including phenyl optionally substituted with halogen, C1 to C4 alkyl or C1 to C4 alkoxy; a dicarboxylic acid such as succinic acid; sulfonate esters such as alkyl or aralkyl sulphonyl including methanesulfonyl; or a mono, di or triphosphate ester; and R4 is hydrogen; C1-C20 alkyl;, acyl, in which the non-carbonyl moiety of the ester group is selected from straight, branched, or cyclic C1-C20 alkyl, phenyl; or benzyl; alkoxyalkyl including methoxymethyl; aralkyl including benzyl; aryloxyalkyl such as phenoxymethyl; aryl including phenyl optionally substituted with halogen, C1 to C4 alkyl or C1 to C4 alkoxy; and wherein the compound is 95% free of its opposite &bgr;-(D or L) enantiomer.